BioCentury
ARTICLE | Company News

Protez, Sumitomo deal

May 23, 2005 7:00 AM UTC

Sumitomo granted an exclusive license to Protez to develop and commercialize SMP-601, a preclinical beta-lactam antibiotic, in North America and Europe. Sumitomo is eligible for milestones and royalti...